Ec Healthcare · HKEX:2138
Ec Healthcare — H1 FY2022/23 Earnings Presentation
22 slides from Ec Healthcare's earnings presentation, November 2022
Slide 1: FY2022/23 Interim Results Investors Presentation
FY2022/23 Interim Results Investors Presentation To bring health, beauty and happiness to everyone 讓世界變得健康、美麗、快樂
Slide 2: Financial Performance
EC Healthcare _ Financial
Slide 3: Key Financial Highlights
Financial Performance INTERIM RESULTS FY22/23 Key Financial Highlights SALES HK$1,812M REVENUE HK$1,893M EBITDA* HK$270M VOLUME • OPEX from New Centers • Steady Sequential • Further Market Share under Renovation & +18.3% • Recovery Strong Local +31.1% • Gain in Medical Segment Strong Momentum with (
Slide 4: Revenue Mix
Financial Performance INTERIM RESULTS FY22/23 Revenue Mix HK$ M HK$ M HK$ M Medical1 1,893 M&A3 1,893 1,893 Aesthetic Medical and Mainland Organic 120 6.3% 90 Beauty and Wellness Macau, China Other2 56 Hong Kong, China 1,444 1,476 1,444 1,476 1,444 1,476 158 (24.1)% 80 +16.3% 93 (3.2)% 10.7% 61 1,17
Slide 5: Sales Volume
Financial Performance INTERIM RESULTS FY22/23 Sales Volume Dec Feb Apr Aug Sep Gradual relaxation of quarantine arrangements for inbound traveller to HK 2021 2022 2022 2022 2022 Compulsory quarantine in hotel 21 14 7 3 0 days days days days days + + 4 days of 3 days of medical medical surveillance s
Slide 6: Continuous Investment to Consolidate Market
Financial Performance INTERIM RESULTS FY22/23 Continuous Investment to Consolidate Market + 69.2% YoY + 24.1% YoY No. of Service Points 154 Total GFA 557,000 q ft s Executed M&A HK$219M* Organic CAPEX HK$ 150M Brand Business Acquired Stake Multi-disciplines 60%** Health Screening 75% Veterinary 75%
Slide 7: Cost & Margin Analysis
Financial Performance INTERIM RESULTS FY22/23 Cost & Margin Analysis EBITDA & EBITDA Margin Net Profit & Net Profit Margin Cost Structure HK$ M HK$ M 75.3% 81.3% to revenue to revenue Cost of medical, 78.0% 13.6% Inventories & to revenue 13.1% Consumables 22.4% 13.6% 400 250 10.9% Rental & lease 14.
Slide 8: Operation Highlights
Operation Highlights
Slide 9: Operation Highlights
Operation Highlights INTERIM RESULTS FY22/23 Operation Highlights Cumulative Network & No. of unique Customer1,6 Number of Panel Doctors visits7,8 No. of 122,883 Discipline & 2,800+ +20.0% YoY 11.8M+ Specialty 35 Repurchase Existing Customer +52.2% YoY Rate2,6 Revenue Contribution3,6 Full Time 93.7%
Slide 10: Post M&A Integration
Operation Highlights INTERIM RESULTS FY22/23 Post M&A Integration Sales CS • 24 x 7 Call Centre • Pre-payment Model • Concierge Service • 1v1 VIP Sales • Digitalized Journey • Corporate Sales Team Pain Management • Sales Force Sharing Medical Specialties Aesthetic Medical Finance Co-Owner Marketing
Slide 11: Digital Transformation – Synergy & Scalability
Operation Highlights INTERIM RESULTS FY22/23 Digital Transformation – Synergy & Scalability Data & AI Customer Digital Way of Working Lower cost/Higher conversion/Better customer experience App & CRM Commercial Partnership Integration/B2B product & service offering Save Cost Operation ERP Utilizatio
Slide 12: Strategy Development
Strategy Development
Slide 13: Capital Management
Strategy Development INTERIM RESULTS FY22/23 Capital Management Average Debt Maturity 3.6 Years TOTAL GEARING DEBT RATIO1 Debt Maturity Profile As at 30 Sep 2022 HK$633M 26.3% 454 +16.2 p.p. HK$ M 236 UNDRAWN CASH ON FACILITIES HAND 103 2 218 HK$300M HK$710M 64 103 12 64 12 2023 2024 2025 2026 Bank
Slide 14: M&A Strategy
Strategy Development INTERIM RESULTS FY22/23 Accretive Acquisition Revenue Growth Complementary To Existing Portfolio M&A Operational Strategy Synergies Optimization Potential for Business Growth Reduction in Value-adding Investment Opportunities 13
Slide 15: Strategic Partnership with Insurance Partner
Strategy Development INTERIM RESULTS FY22/23 Strategic Partnership with Insurance Partner AXA Medical Centre Property Telecommunication Insurance EC HEALTHCARE Technology ECOSYSTEM Pharmaceutical 14
Slide 16: Strategic Partnership with Property, Telecom & Technology Partners
Strategy Development INTERIM RESULTS FY22/23 Strategic Partnership with Property, Telecom & Technology Partners Deployment of IoT Solution to Build a Property State-of-art Medical Office Building Pharmaceutical Telecommunication Insurance EC HEALTHCARE ECOSYSTEM Technology 15
Slide 17: Outlook
Outlook
Slide 18: Outlook
Strategy Development INTERIM RESULTS FY22/23 Outlook Navigate Through “Normalization” Strategic Partnership to Build to Drive Organic Growth Healthcare Ecosystem • Operation environment remains challenging • Continue to expand our strategic partnerships • Stay optimistic and expect a prudent recover
Slide 19: EC Healthcare
EC Healthcare SER estore Cade: 2158
Slide 20: Appendix
EC Healthcare rippansles
Slide 21: Key Financial Metrics
Appendix INTERIM RESULTS FY22/23 Key Financial Metrics For the six months ended 30 September 1H FY21/22 1H FY22/23 Changes Basic Earnings per share (HK cents) 14.2 6.8 (52.1)% EBITDA margin 22.4% 14.3% (8.1) p.p. Net profit margin 13.6% 5.6% (8.0) p.p. Dividend per share for the year (HK cents) 10.2
Slide 22: Disclaimer
INTERIM RESULTS FY22/23 Disclaimer Financial Results For the year ended 31 March This document does not constitute or form part of and should not be construed as, an offer to sell or issue or the solicitation of an offer to buy or acquire securities (the “Securities”) of EC Healthcare (the "Company"